Abstract: The present disclosure is directed, in general, to (1) nonlinear optical (NLO) chromophores containing spirofluorene-isophorone bridging groups, including (2) compositions/materials/resistive layers comprising NLO chromophores containing spirofluorene-isophorone bridging groups, and the methods of making the compositions/materials/resistive layers comprising NLO chromophores containing spirofluorene-isophorone bridging groups (e.g., methods of poling and/or drying, and the like), (3) uses of NLO chromophores containing spirofluorene-isophorone bridging groups in electro-optic devices (e.g., EOMs).

Abstract: Nonlinear optical chromophore compositions which display lyotropic nematic liquid crystal phases in polar organic solvents and provide a mechanical anisotropic effect allowing for the formation of a non-centrosymmetric chromophore-polymer matrix without the application of an electric field.

Abstract: The present invention is directed, in general, to nonlinear optical chromophores having a Michler's base-type group. Various embodiments of the present invention include nonlinear optical chromophores with Michler's base-type group having a Michler's base donor group connected to a ?-bridge group. Various embodiments of the present invention include nonlinear optical chromophores with Michler's base-type group having high photostability, which chromophores can reduce the percentage of being deactivated by molecular oxygen under illumination.

Abstract: The present invention is directed, in general, to nonlinear optical chromophores having an indolizine donor group. Various embodiments of the present invention include nonlinear optical chromophores with indolizine donor group having an indolizine donor connected to a II-bridge group. In various preferred embodiments of the present invention, the indolizine donor groups may be substituted or unsubstituted, including hydro and alkyl substituents, aryl substituents and combination thereof. In certain embodiments of the present invention, the substituent moieties in the indolizine donor groups may be important for isolation. The isolation may reduce chromophore-chromophore interaction. The isolation may reduce charge transfer between molecules. The isolation may increase maximum applied voltage, which may contribute to more optimal poling and higher r33.

Abstract: Nonlinear optical chromophore compositions which display lyotropic nematic liquid crystal phases in polar organic solvents and provide a mechanical anisotropic effect allowing for the formation of a non-centrosymmetric chromophore-polymer matrix without the application of an electric field.

Abstract: Nonlinear optical chromophore compositions which display lyotropic nematic liquid crystal phases in polar organic solvents and provide a mechanical anisotropic effect allowing for the formation of a non-centrosymmetric chromophore-polymer matrix without the application of an electric field.

Abstract: Nonlinear optical chromophore compositions which display lyotropic nematic liquid crystal phases in polar organic solvents and provide a mechanical anisotropic effect allowing for the formation of a non-centrosymmetric chromophore-polymer matrix without the application of an electric field.

Abstract: Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Nonlinear optical chromophores are provided that have a short chain bridging group between donor and acceptor, which chromophores exhibit lowered ?max values and narrow absorption bands. Electro-optic films prepared from nonlinear optical chromophores provided have enhanced transparency to wavelengths outside of the narrow absorption bands, as well as low optic loss, high thermal stability, and high photostability.

Abstract: Nonlinear optical chromophore compositions which display lyotropic nematic liquid crystal phases in polar organic solvents and provide a mechanical anisotropic effect allowing for the formation of a non-centrosymmetric chromophore-polymer matrix without the application of an electric field.

Abstract: The present invention is directed, in general, to compositions containing electro-optic materials and high boiling point solvents allowing for improved, more efficient poling, as well as methods of poling such materials. Various embodiments of the present invention thus provide materials with excellent electro-optic properties which can be efficiently poled for use in electro-optic devices. In the various embodiments of the present invention, materials can be applied as thin films and efficiently poled at low temperatures with normally applied voltage, while simultaneously exhibiting excellent nonlinear optical macroscopic properties and thermal stability.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: [INSERT FORMULA I] and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and Ry have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and R3 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and R3 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: [INSERT FORMULA I] and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and Ry have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.